On March 12, 2026, global biotechnology and pharmaceutical markets were in focus on Thursday as investors tracked a mix of obesity drug data, clinical research investment and manufacturing expansion in APAC region. Among the most closely watched updates, Regeneron and Hansoh Pharma reported phase 3 results for olatorepatide, a dual GLP-1/GIP receptor agonist, showing average … Global and APAC Biopharma Watch: Capital Raising, Clinical Expansion, and Industry Moves in Focus Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.